#USA #Scottsdale #CND Life Sciences #Syn-One Test #Neurodiagnostics

CND Life Sciences Achieves Milestone of 50,000 Syn-One Tests

CND Life Sciences, a trailblazer in the field of medical technology, has proudly announced a significant achievement with the completion of its 50,000th Syn-One Test, a skin biopsy-based diagnostic tool aimed at aiding clinicians in identifying synucleinopathies. This milestone reflects the growing reliance on innovative solutions in the medical field, particularly in the complex realm of neurodegenerative diseases.

Background of the Syn-One Test

Launched in 2019, the Syn-One Test quickly gained traction among neurologists and other healthcare professionals across all 50 states. This laboratory developed test (LDT) is specifically designed to support the diagnosis of various conditions related to synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). The test involves a straightforward outpatient skin biopsy procedure, making it accessible for both patients and clinicians.

Richard Morello, CEO of CND Life Sciences, expressed gratitude to the team and co-founders for their contributions toward reaching this pivotal moment. He stated, "Neurologists and other clinicians continue to express their earnest appreciation for the Syn-One Test, as it provides valuable information to help diagnose synucleinopathies, which are complex neurological conditions that are often difficult to accurately identify."

The Science Behind the Test

What sets the Syn-One Test apart is its unique ability to visually detect and quantify phosphorylated alpha-synuclein (P-SYN) in cutaneous nerves. By utilizing three small skin biopsy samples taken from specific anatomical sites on a patient's body, the test effectively identifies abnormal P-SYN proteins while measuring peripheral nerve damage and evaluating skin morphology.

In a pioneering study funded by the National Institutes of Health (NIH), the Syn-One Test demonstrated an impressive sensitivity and specificity of over 95% among patients diagnosed with various forms of synucleinopathies. The ongoing Syn-Sleep Study is also exploring the potential of the Syn-One Test as an early detection tool for patients exhibiting symptoms of idiopathic REM sleep behavior disorder (iRBD), a condition which may precede the development of synucleinopathies.

The Need for Accessible Diagnostics

Dr. Christopher Gibbons, Chief Scientific Officer at CND Life Sciences and a professor at Harvard Medical School, highlighted the importance of accessible diagnostic tools in the field of neurology. He noted, "There are an estimated 2.5 million people in the U.S. diagnosed with a synucleinopathy, with around 180,000 new cases arising each year. The Syn-One Test has filled a crucial gap in the diagnostic process for clinicians, helping them to provide better care for their patients."

The test not only assists in diagnosis but also significantly impacts treatment planning. Over half of the cases reviewed in a recent independent study saw adjustments in clinical diagnosis or patient management, indicating the practical benefits of incorporating the Syn-One Test into routine clinical practice.

Real-World Impact

Healthcare professionals emphasize the importance of swift and accurate diagnoses in the field of neurology. Dr. Kenneth M. Carnes, a board-certified neurologist at Raleigh Neurology Associates in North Carolina, stated, "When I see patients presenting with symptoms of a synucleinopathy, the Syn-One Test provides an essential tool for accurate diagnosis and allows us to determine the most appropriate treatment strategy."

The impact of this test extends beyond individual diagnoses, as it can alleviate uncertainty and anxiety for families dealing with neurodegenerative diseases. Andrea Merriam, CEO of the patient advocacy organization Parkinson Movement Disorder Alliance, remarked, "Tools like the Syn-One Test are essential for helping families understand their situation and make informed decisions about their future healthcare options."

Conclusion

CND Life Sciences is committed to advancing the care of patients who may be facing neurodegeneration. The 50,000th Syn-One Test is a testament to the importance of innovation in medical diagnostics. With a dedicated laboratory located in Scottsdale, Arizona, and collaborations with various biopharmaceutical companies, CND Life Sciences is steadfast in its mission to transform the diagnosis and management of synucleinopathies, ultimately contributing to better patient outcomes and paving the way for future advancements in the field.

For more information about CND Life Sciences and the Syn-One Test, visit their official website.